Advaxis Inc.
ADXS
OTCQX
Sector: Healthcare
Industry: Biotechnology
0.06
USD
0.00
(-6.01%)
Optionable: No Market Cap: 10 M 90-day average vol: 499,352
Previous close: 0.06905 Open: 0.0655 Bid: Ask:
52 week range
0.06 0.71
Last updated: Friday 20th May 2022
Valuation
Price per Sales TTM ($) | 39.61 |
Price per Book TTM ($) | 0.25 |
PE Ratio (TTM) | -0.60 |
Book Value per Share ($) | 0.26 |
5 Year PE Range-3.4 |
Returns
7 Day Return | -7.29% | |
1 Month Return | -27.89% | |
3 Month Return | -41.00% | |
1 Year Return | -88.73% | |
3 Year Return | -97.85% | |
5 Year Return | -99.95% | |
YTD Return | -58.29% |
Risk
Custom Beta One Year | 0.00 |
Custom Beta Three Years | 0.00 |
Beneish M Score | 0.00 |
Altman Z Score | -12.27 |
Financial Health
Technicals
RSI (14 Day) | 35.53 |
14 Day SMA ($) | 0.07 |
14 Day EMA ($) | 0.07 |
Money Flow Index | 62.88 |
Average True Range | 0.01 |
50 Day SMA ($) | 0.10 |
200 Day SMA ($) | 0.28 |
ADX | 18.08 |
MACD | -0.01 |
Growth
Free Cash Flow QoQ Growth | 35.51% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | 100.00% |
Revenue QoQ Growth | -100.00% |
EPS YoY Growth | 0.00% |
Profitability
Advaxis Reports Fiscal Year 2021 Financial Results and Provides a Business Update
Yahoo Finance 2/14/2022
Advaxis prices $5M in convertible redeemable preferred stock offering
Seeking Alpha 1/28/2022
Advaxis Prices Offering of $5,000,000 of Convertible Redeemable Preferred Stock Through a Private Placement
Yahoo Finance 1/28/2022
Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC and Upcoming Milestones
Yahoo Finance 1/11/2022
OTC Markets Group Welcomes Advaxis, Inc. to OTCQX
Yahoo Finance 12/23/2021
Advaxis to start trading on OTCQX on Dec 23
Seeking Alpha 12/22/2021
Advaxis Announces Acceptance for Trading on the OTCQX
Yahoo Finance 12/22/2021
Advaxis wins shareholder approval for Biosight merger
Seeking Alpha 12/17/2021
Advaxis to Continue to Explore Additional Options to Maximize Stockholder Value
Yahoo Finance 12/17/2021
Advaxis Issues Letter to Stockholders Regarding Recent Special Meeting Results
Yahoo Finance 12/9/2021
Advaxis Issues Letter and Second Video Message to Stockholders Regarding Upcoming Special Meeting
Yahoo Finance 11/24/2021
Nasdaq Grants Advaxis, Inc. an Extension to December 20, 2021, to Complete Merger Transaction with Biosight, Ltd. and Satisfy Initial Listing Requirements
Yahoo Finance 11/22/2021
Advaxis, Inc. Issues Letter to Stockholders
Yahoo Finance 11/19/2021
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Advaxis Stockholders Vote “FOR” Proposed Merger with Biosight
Yahoo Finance 11/18/2021
Biosight Encourages Advaxis Stockholders to Vote “FOR” Proposed Merger
Yahoo Finance 11/11/2021
Advaxis Issues Letter and Video Message to Stockholders Regarding Upcoming Special Meeting
Yahoo Finance 11/4/2021
| NA |
|---|
| could not broadcast input array from shape (20) into shape (0) |
|---|
ADXS Income Statement
Annual
| Oct-12 | Oct-13 | Oct-14 | Oct-15 | Oct-16 | Oct-17 | Oct-18 | Oct-19 | Oct-20 | |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 1000000 | 0 | 4 M | 12 M | 6 M | 21 M | 253000 |
| Cost of sales | -2 M | -178636 | -203297 | -325998 | -788922 | -1 M | -2 M | -1 M | -2 M |
| Gross operating profit | 0 | 0 | 1000000 | 0 | 4 M | 12 M | 6 M | 21 M | 253000 |
| Selling Gen & administrative expense | 6 M | 9 M | 12 M | 24 M | 32 M | 40 M | 19 M | 12 M | 11 M |
| Research & development expense | 7 M | 6 M | 9 M | 24 M | 49 M | 71 M | 57 M | 27 M | 16 M |
| Operating income | -12 M | -15 M | -20 M | -49 M | -76 M | -98 M | -70 M | -18 M | -26 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | 4 M | -5 M | 620079 | -55549 | 68854 | -62000 | 3 M | 975000 | -80000 |
| Pre-tax Income (EBT) | -12 M | -21 M | -19 M | -49 M | -76 M | -98 M | -66 M | -17 M | -26 M |
| Income taxes | -346787 | -725190 | -2 M | -2 M | -3 M | -4 M | 50000 | 50000 | 50000 |
| Net income from total operations | -12 M | -20 M | -17 M | -47 M | -74 M | -93 M | -67 M | -17 M | -26 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | -12 M | -20 M | -17 M | -47 M | -74 M | -93 M | -67 M | -17 M | -26 M |
| Preferred dividends | 740000 | 555000 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net income available for common | -13 M | -21 M | -17 M | -47 M | -74 M | -93 M | -67 M | -17 M | -26 M |
| Depreciation | 2 M | 178636 | 203297 | 325998 | 788922 | 1 M | 2 M | 1 M | 2 M |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income before depreciation (EBITDA) | -8 M | -20 M | -19 M | -48 M | -76 M | -97 M | -69 M | -16 M | -24 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | -75 | -61.5 | -14.55 | -25.2 | -31.2 | -34.65 | -19.36 | -1.09 | -0.43 |
| Diluted EPS total | -75 | -61.5 | -14.55 | -25.2 | -31.2 | -34.65 | -19.36 | -1.09 | -0.43 |
Top MarketXLS Rank stocks
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!